|
|
(HealthNewsDigest.com) – A U.S. Food and Drug Administration panel backed keeping GlaxoSmithKline’s Avandia on the U.S. market, though the panel had concerns about clinical data regarding the diabetes drug. The panel also said Avandia appeared to have more cardiovascular risks compared to a competitor drug, Actos.
http://online.wsj.com/article/SB10001424052748704220704575367240487934902.html?mod=djemalertNEWS
Subscribe to our FREE Ezine and receive current Health News, be eligible for discounted products/services and coupons related to your Health. We publish 24/7.
HealthNewsDigest.com
For advertising/promotion, email: [email protected] Or call toll free: 877- 634-9180